Evaluation of Ki-67 and Bcl-2 antigen expression in breast carcinomas of women treated with raloxifene.
OBJECTIVE
To evaluate the effect of raloxifene on Ki-67 and Bcl-2 antigen expression in operable, stage II, oestrogen-receptor-positive invasive ductal breast carcinomas.


METHODS
Twenty post-menopausal women who had taken 60 mg of raloxifene daily for 28 days prior to definitive surgery were enrolled in the investigation. Two tumour samples were obtained by incisional biopsy during the study, one at the time of confirmation of diagnosis of invasive ductal carcinoma and evaluation of oestrogen receptor status, and the other 29 days later, at the time of definitive surgery. Immunohistochemistry was performed on tumour samples, prior to and after raloxifene treatment, to evaluate Ki-67 and Bcl-2 expression. Friedman and McNemar tests were used for statistical analysis of the data, significance being established at 5%.


RESULTS
Mean percentage of Ki-67-stained nuclei was 24.86 +/- 2.95 prior to raloxifene treatment and 13.33 +/- 1.52 after treatment (P < 0.001). Prior to raloxifene treatment, only 9/20 cases (45%) were classified as Bcl-2-positive, whereas after treatment, 17/20 (85%) were classified as Bcl-2-positive (P < 0.013).


CONCLUSIONS
Raloxifene treatment significantly reduced Ki-67 antigen expression and increased Bcl-2 expression in breast carcinomas of post-menopausal women.
Lopes-Costa
P V
PV
Department of Gynecology, Mastology Division, Hospital Getúlio Vargas, Federal University of Piauí, Teresina, Piauí, Brazil.
dos Santos
A R
AR
dos Santos
L G
LG
da Silva
B B
BB
D000368:Aged; D001706:Biopsy; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002467:Cell Nucleus / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism*; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000032:analysis; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
D019394:Ki-67 Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride
Arch Pathol Lab Med. 2000 Jul;124(7):966-78
10888772
Br J Cancer. 1996 Jul;74(1):78-85
8679463
JAMA. 2006 Jun 21;295(23):2727-41
16754727
Cancer Res. 1994 Jul 15;54(14):3714-7
8033089
Mod Pathol. 2005 Mar;18(3):374-81
15578079
Int J Cancer. 2002 Mar 1;98(1):118-27
11857395
Eur J Cancer. 2004 Jan;40(2):205-11
14728934
Philos Trans R Soc Lond B Biol Sci. 1994 Aug 30;345(1313):269-75
7846125
BMC Cancer. 2008 May 29;8:153
18510726
Breast Cancer Res Treat. 2001 Jan;65(2):125-34
11261828
Mod Pathol. 1998 Mar;11(3):259-64
9521472
Eur J Gynaecol Oncol. 2008;29(5):459-61
19051812
Br J Cancer. 1993 Mar;67(3):606-11
8439511
Cancer. 2002 Apr 15;94(8):2151-9
12001111
Breast Cancer. 2008;15(4):262-9
18654829
Breast Cancer Res Treat. 1998 Mar;48(1):11-20
9541185
Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1024s-1030s
16467120
Eur J Cancer. 1994;30A(11):1663-9
7833141
Cancer Treat Rev. 2007 Apr;33(2):91-100
17178195
Int J Gynaecol Obstet. 2006 Oct;95(1):64-5
16828763
Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):961-6
11535548
J Natl Cancer Inst. 1994 Apr 6;86(7):499-504
8133533
J Natl Cancer Inst. 2009 Mar 18;101(6):384-98
19276457
Gynecol Obstet Invest. 2009;67(2):103-8
18953168
Curr Med Res Opin. 2005 Sep;21(9):1441-52
16197663